Skip to main content

Research Repository

Advanced Search

All Outputs (9)

A novel dietary intervention reduces circulatory branched-chain amino acids by 50%: A pilot study of relevance for obesity and diabetes (2020)
Journal Article
Ramzan, I., Taylor, M., Phillips, B., Wilkinson, D., Smith, K., Hession, K., …Atherton, P. (2021). A novel dietary intervention reduces circulatory branched-chain amino acids by 50%: A pilot study of relevance for obesity and diabetes. Nutrients, 13(1), Article 95. https://doi.org/10.3390/nu13010095

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Elevated circulating branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) are associated with obesity and type 2 diabetes (T2D). Reducing circulatory BCAAs by dietary restrictio... Read More about A novel dietary intervention reduces circulatory branched-chain amino acids by 50%: A pilot study of relevance for obesity and diabetes.

Phenylbutyrate, a branched-chain amino acid keto dehydrogenase activator, promotes branched-chain amino acid metabolism and induces muscle catabolism in C2C12 cells (2020)
Journal Article
Crossland, H., Smith, K., Idris, I., Phillips, B. E., Atherton, P. J., & Wilkinson, D. J. (2021). Phenylbutyrate, a branched-chain amino acid keto dehydrogenase activator, promotes branched-chain amino acid metabolism and induces muscle catabolism in C2C12 cells. Experimental Physiology, 106(3), 585-592. https://doi.org/10.1113/EP089223

New Findings: What is the central question of this study? The compound sodium phenylbutyrate (PB) has been shown to promote branched-chain amino acid (BCAA) catabolism, and as such has been proposed as a treatment for disorders with enhanced BCAA lev... Read More about Phenylbutyrate, a branched-chain amino acid keto dehydrogenase activator, promotes branched-chain amino acid metabolism and induces muscle catabolism in C2C12 cells.

Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations (2020)
Journal Article
Alshnbari, A., Alkharaiji, M., Anyanwagu, U., & Idris, I. (2020). Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations. Current Medical Research and Opinion, 36(12), 1985-1989. https://doi.org/10.1080/03007995.2020.1840340

Aims and background: Sodium-glucose cotransporter-2 (SGLT2) inhibitor has been linked to an increased risk of lower extremity amputation (LEA) in patients with Type 2 Diabetes (T2D) and is known to induce volume depletion through osmotic diuresis. We... Read More about Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations.

Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle (2020)
Journal Article
Abdulla, H., Phillips, B. E., Wilkinson, D. J., Limb, M., Jandova, T., Bass, J. J., …Atherton, P. J. (2020). Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell, 19(9), Article e13202. https://doi.org/10.1111/acel.13202

© 2020 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd Background: Despite its known insulin-independent effects, glucagon-like peptide-1 (GLP-1) role in muscle protein turnover has not been explored under fed-stat... Read More about Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle.

Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies (2020)
Journal Article
Alshnbari, A. S., Millar, S. A., O’Sullivan, S. E., & Idris, I. (2020). Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies. Diabetes Therapy, 11, 1947–1963. https://doi.org/10.1007/s13300-020-00885-z

Introduction While the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on cardiovascular and renal outcomes are recognized, their direct effects on endothelial function remain unclear. We, therefore, undertook a systematic... Read More about Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.

Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database (2020)
Journal Article
Alkharaiji, M., Anyanwagu, U., Donnelly, R., & Idris, I. (2020). Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database. Obesity Surgery, 30(5), 1685–1695. https://doi.org/10.1007/s11695-019-04201-y

Aims: To compare the effect of bariatric surgery on renal, chronic kidney disease (CKD), and cardiovascular (CV) outcomes among obese patients with insulin-treated type 2 diabetes (T2D) with and without microalbuminuria (i.e. uACR > 3.0 mg/mmol).... Read More about Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database.

Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery (2020)
Journal Article
Antipass, A., Austin, A., Awad, S., Hughes, D., & Idris, I. (2020). Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery. Obesity Surgery, 30, 2840–2843. https://doi.org/10.1007/s11695-020-04486-4

Bariatric and metabolic surgery is associated with significant improvement in obesity-related comorbidities, but for patients with non-alcoholic fatty liver disease (NAFLD), clinical outcomes are dependent on the severity of liver disease, i.e. impro... Read More about Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery.

Endocannabinoids in aqueous humour of patients with or without diabetes (2020)
Journal Article
Richardson, P. S., Ortori, C., Barrett, D. A., O'Sullivan, S. E., & Idris, I. (2020). Endocannabinoids in aqueous humour of patients with or without diabetes. BMJ Open Ophthalmology, 5(1), https://doi.org/10.1136/bmjophth-2019-000425

Objective The primary aim was to determine endocannabinoid (EC) concentrations of 2-arachidonoylglycerol (2-AG), oleoylethanolamine (OEA), palmitoylethanolamine (PEA) and anandamide (AEA) in the aqueous humour of patients, and to investigate any diff... Read More about Endocannabinoids in aqueous humour of patients with or without diabetes.